MY130957A - Triazine derivatives and their application as antitelomerase agents - Google Patents

Triazine derivatives and their application as antitelomerase agents

Info

Publication number
MY130957A
MY130957A MYPI20021036A MYPI20021036A MY130957A MY 130957 A MY130957 A MY 130957A MY PI20021036 A MYPI20021036 A MY PI20021036A MY PI20021036 A MYPI20021036 A MY PI20021036A MY 130957 A MY130957 A MY 130957A
Authority
MY
Malaysia
Prior art keywords
agents
antitelomerase
application
triazine derivatives
relates
Prior art date
Application number
MYPI20021036A
Inventor
Mailliet Patrick
Mergny Jean-Louis
Laoui Abdelazize
Riou Jean-Francois
Doerflinger Gilles
Hamy Francois
Caulfield Thomas
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0103916A external-priority patent/FR2822468B1/en
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MY130957A publication Critical patent/MY130957A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

THE PRESENT INVENTION RELATES TO CENCER THERAPY AND TO NOVEL ANTICANCER AGENTS HAVING A SPECIFIC MECHANISM OF ACTION. IT ALSO RELATES TO NOVEL CHEMICAL COMPOUNDS AS WELL AS THEIR THERAPEUTIC IN HUMANS.
MYPI20021036A 2001-03-23 2002-03-22 Triazine derivatives and their application as antitelomerase agents MY130957A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0103916A FR2822468B1 (en) 2001-03-23 2001-03-23 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTI-TELOMERASE AGENT
FR0110370 2001-08-02

Publications (1)

Publication Number Publication Date
MY130957A true MY130957A (en) 2007-07-31

Family

ID=26212933

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20021036A MY130957A (en) 2001-03-23 2002-03-22 Triazine derivatives and their application as antitelomerase agents

Country Status (11)

Country Link
EP (1) EP1373252A1 (en)
JP (1) JP2004524349A (en)
AR (1) AR034297A1 (en)
AU (1) AU2002251140B2 (en)
CA (1) CA2442012A1 (en)
CO (1) CO5380035A1 (en)
IL (2) IL158056A0 (en)
MX (1) MXPA03008269A (en)
MY (1) MY130957A (en)
PE (1) PE20020959A1 (en)
WO (1) WO2002076975A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096903A2 (en) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003253735A1 (en) * 2002-06-25 2004-01-06 The Center For Blood Research, Inc. Vacuolins
FR2850970B1 (en) * 2003-02-07 2006-07-07 Aventis Pharma Sa CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2008540585A (en) * 2005-05-19 2008-11-20 プロメティック・バイオサイエンスィズ・インコーポレーテッド Compounds for treating metastatic melanoma and other cancers, compositions containing such compounds, and methods of treatment
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
ES2392003T3 (en) * 2007-07-25 2012-12-03 Bristol-Myers Squibb Company Triazine Kinase Inhibitors
FR2948686B1 (en) * 2009-07-30 2011-08-19 Biomerieux Sa NEW PEPTIDASE SUBSTRATES
JP7284518B2 (en) * 2018-03-20 2023-05-31 国立大学法人広島大学 Compound that inhibits telomere-binding protein, and telomere-binding protein inhibitor containing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (en) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd Triazine derivative and telomerase inhibitor
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
CA2392507A1 (en) * 1999-11-29 2001-06-07 Aventis Pharma S.A. Arylamine derivatives and their use as anti-telomerase agent
CN1625410A (en) * 2002-02-05 2005-06-08 山之内制药株式会社 2,4,6-triamino-1,3,5-triazine derivative

Also Published As

Publication number Publication date
IL158056A0 (en) 2004-03-28
CO5380035A1 (en) 2004-03-31
AR034297A1 (en) 2004-02-18
AU2002251140B2 (en) 2007-03-15
JP2004524349A (en) 2004-08-12
EP1373252A1 (en) 2004-01-02
CA2442012A1 (en) 2002-10-03
PE20020959A1 (en) 2002-12-17
IL158056A (en) 2010-02-17
MXPA03008269A (en) 2004-10-15
WO2002076975A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
IL149402A0 (en) Arylamine derivatives and their use as anti-telomerase agent
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
EP1432714A4 (en) Chemical compounds
DE60112974D1 (en) Carbolinderivate
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MY128924A (en) Novel compounds
MXPA04003796A (en) Substituted thioacetamides.
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
MXPA03007142A (en) Chemical compounds.
HUP0500424A2 (en) Combination therapy for the treatment of cancer
ZA200500908B (en) Ruthenium anticancer complexes
MXPA03010761A (en) Pharmaceutical combinations.
PT1463735E (en) Imidazo¬2,1-b -1,3,4-thiadiazole sulfonamides
GB0018951D0 (en) Novel compounds
YU8804A (en) Single dose azithromycin
PL368737A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
PT1303520E (en) Therapeutic compounds and methods
MXPA04004090A (en) Substituted 1h-quinolin-2-one compounds.
AU2001280754A1 (en) Enhancement of photodynamic therapy by anti-angiogenic treatment
EP1436279A4 (en) Chemical compounds
HK1054506A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof